| abstract |
A humanized antibody capable of specifically binding to a human CEACAM1 molecule, and a polynucleotide sequence encoding the same, that contain a return mutation from human to murine in a non-CDR variable region. As well as pharmaceutical compositions comprising said antibodies, as well as methods of use thereof in cancer and other condition therapy and diagnosis. |